Swiss Drugmaker Novartis

• 

  Swiss Drugmaker Novartis To Help Make Pfizer-Biontech Coronavirus Vaccine

  Swiss drugmaker Novartis has signed an initial agreement to provide manufacturing capacity for Pfizer and Biontech's COVID-19 vaccine, a move aimed at helping boost production as supplies fall shy of demand.

• 

  Novartis India Says Unaware of Any Delisting Plan

  Earlier on Thursday, Bloomberg reported citing people with knowledge of the matter that Swiss drugmaker Novartis AG, which owns three quarters of Novartis India, was considering buying all the shares it didn't already own in the arm.

• 

  Heart Drug Launch Could be 'Most Exciting Ever', Says Novartis

  The Swiss drugmaker impressed doctors at the European Society of Cardiology meeting in Barcelona at the weekend by unveiling strikingly good clinical trial results for the drug, known as LCZ696, in a keenly awaited clinical trial.

• Heart Drug Could Be "Most Exciting Ever", Says Novartis

  Swiss drugmaker Novartis has unveiled strikingly good clinical trial results for a new heart failure drug that might be the biggest pharmaceutical advance in a quarter of century.

• Novartis and Google to Develop 'Smart' Contact Lens

  Swiss drugmaker Novartis has struck an agreement with Google to develop "smart" contact lenses that would help diabetics track their blood glucose levels or restore the eye's ability to focus.

• Drugmaker Novartis files patent suit against Biocon over diabetes drug

  Novartis has taken Biocon to court for infringing the patent on its diabetes drug Galvus, the Swiss drugmaker said in a statement on Thursday.

• Dr Reddy's recalls some lots of lansoprazole in US

  Dr. Reddy's voluntary recall of lansoprazole delayed release capsules, a generic version of Swiss drugmaker Novartis' drug Prevacid 24 HR, began on January 3, 2014, the FDA said on its website.

• US sues Novartis over kickbacks, second case this week

  The US government on Friday announced its second civil fraud lawsuit against Novartis AG in four days, accusing a unit of the Swiss drugmaker of paying multimillion-dollar kickbacks to doctors in exchange for prescribing its drugs.

• Post Supreme Court verdict, Novartis to invest in India 'cautiously'

  Swiss drugmaker Novartis AG will continue to invest in India, the vice chairman and managing director of the company said today after the Supreme Court dismissed the pharmaceutical major's plea for patent protection of its cancer drug Glivec.

• Novartis on patent setback: Will continue to invest in India, but cautiously

  Novartis India Limited, a unit of Swiss drugmaker Novartis AG, will continue to file for patents in India, its vice chairman said on Monday, after the country's top court rejected its plea for patent protection of its drug Glivec.

• Novartis judgement: What it means for you

  The Supreme Court on Monday rejected Swiss drugmaker Novartis AG's plea for patent protection of its cancer drug Glivec. The Supreme Court's decision comes after a legal battle that began when Novartis was denied a patent for Glivec in 2006.

• Novartis: Will continue with our investments in India, although catiously

  The Supreme Court today rejected Swiss drugmaker Novartis AG's plea for a patent protection of its cancer drug Glivec, a move likely to boost the prospects of Indian pharmaceutical firms over foreign ones.

• Supreme Court rejects Novartis AG's plea for cancer drug patent: Read full verdict

  The Supreme Court has dismissed Swiss drugmaker Novartis AG's attempt to win patent protection for its cancer drug Glivec, a serious blow to Western pharmaceutical firms who are increasingly focusing on India to drive sales. Here is the copy of the full verdict:

• Novartis AG's plea for Glivec patent dismissed by Supreme Court

  The Supreme Court dismissed Swiss drugmaker Novartis AG's attempt to win patent protection for its cancer drug Glivec, a blow to Western pharmaceutical firms targeting India to drive sales and a victory for local makers of cheap generics.

• Novartis shares fall 7% after Supreme Court rejects patent for cancer drug

  Shares in drug maker Novartis AG fell sharply after the Supreme Court ruled that the Swiss giant's cancer treatment Glivec does not deserve a patent in India. The ruling was being closely watched by global drugmakers who have been battered by recent intellectual property decisions in India.